{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:04Z","timestamp":1790710144402,"version":"4.1.0"},"reference-count":41,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s293698","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T20:31:36Z","timestamp":1614198696000},"page":"145-153","source":"Crossref","is-referenced-by-count":13,"title":["Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database"],"prefix":"10.2147","volume":"Volume 13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6860-8050","authenticated-orcid":true,"given":"Tsugumi","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nbt0910-917","volume":"28","author":"Walsh","year":"2010","journal-title":"Nat Biotechnol"},{"key":"ref2","unstructured":"National Institute of Health Sciences, 2019. List of approved biologics 2020. (In Japanese). Available from: http:\/\/www.nihs.go.jp\/dbcb\/approved_biologicals.html. Accessed September 25, 2020."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3892\/ol.2019.11105","volume":"19","author":"Konstantinidou","year":"2020","journal-title":"Oncol Lett"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jiph.2019.11.015","volume":"13","author":"Rabaan","year":"2020","journal-title":"J Infect Public Health"},{"key":"ref5","unstructured":"Ministry of Health, Labour and Welfare, Japan. Update of drug pricing system in Japan 2018. Available from: https:\/\/www.mhlw.go.jp\/content\/11123000\/000335166.pdf. Accessed September 25, 2020."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biologicals.2020.02.005","volume":"65","author":"Kang","year":"2020","journal-title":"Biologicals"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.xphs.2017.10.040","volume":"107","author":"Kuribayashi","year":"2018","journal-title":"J Pharm Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"104525","DOI":"10.1016\/j.yrtph.2019.104525","volume":"110","author":"Rathore","year":"2020","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref9","first-page":"397","volume":"47","author":"Yonezawa","year":"2020","journal-title":"Jpn J Cancer Chemother"},{"key":"ref10","unstructured":"Generics and Biosimilars Initiative. Biosimilars approved in Japan. Available from: http:\/\/gabionline.net\/Biosimilars\/General\/Biosimilars-approved-in-Japan. Accessed September 25, 2020."},{"key":"ref11","unstructured":"Ministry of Health, Labour and Welfare, Japan. What\u2019s new 2018. Available from: https:\/\/www.mhlw.go.jp\/english\/new-info\/2018.html. Accessed September 25, 2020."},{"key":"ref12","first-page":"193","volume":"76","author":"Goto","year":"2019","journal-title":"Jpn J Med Pharm Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/BTT.S207246","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"key":"ref14","unstructured":"Ministry of Health, Labour and Welfare, Japan. An outline of the Japanese medical system. Available from: https:\/\/www.mhlw.go.jp\/bunya\/iryouhoken\/iryouhoken01\/dl\/01_eng.pdf. Accessed September 25, 2020."},{"key":"ref15","unstructured":"Ministry of Health, Labour and Welfare, Japan. High-cost medical expense benefit (eligibility certificate for ceiling-amount application) or KOGAKU RYOYOHI SEIDO (GENDOGAKU TEKIYO NINTEISHO) 2018. Available from: https:\/\/www.mhlw.go.jp\/seisakunitsuite\/bunya\/kenkou_iryou\/iryou\/kokusai\/setsumeisiryo\/dl\/en09.pdf. Accessed September 25, 2020."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0168-8510(02)00199-9","volume":"64","author":"Nakatani","year":"2003","journal-title":"Health Policy (New York)"},{"key":"ref17","unstructured":"Ministry of Health, Labour and Welfare, Japan. Intractable disease measures. Available from: https:\/\/www.mhlw.go.jp\/english\/wp\/wp-hw5\/dl\/23010223e.pdf. Accessed September 25, 2020."},{"key":"ref18","unstructured":"Ministry of Health, Labour and Welfare, Japan. Summary of diagnosis procedure combination system and its basic concept. (In Japanese). Available from: https:\/\/www.mhlw.go.jp\/stf\/shingi\/2r985200000105vx-att\/2r98520000010612.pdf. Accessed September 25, 2020."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.healthpol.2012.01.002","volume":"107","author":"Hamada","year":"2012","journal-title":"Health Policy (New York)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/03007995.2019.1699519","volume":"36","author":"Oh","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40119-019-0142-5","volume":"8","author":"Winburn","year":"2019","journal-title":"Cardiol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2018.12.026","volume":"282","author":"Wake","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40801-019-0150-8","volume":"6","author":"Sakata","year":"2019","journal-title":"Drugs Real World Outcomes"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/03007995.2018.1551192","volume":"35","author":"Nishimura","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e025806","DOI":"10.1136\/bmjopen-2018-025806","volume":"9","author":"Nishimura","year":"2019","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2018.03.023","volume":"272","author":"Wake","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40801-018-0136-y","volume":"5","author":"Matsui","year":"2018","journal-title":"Drugs Real World Outcomes"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e018553","DOI":"10.1136\/bmjopen-2017-018553","volume":"8","author":"Imai","year":"2018","journal-title":"BMJ Open"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.atherosclerosis.2016.07.001","volume":"251","author":"Teramoto","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/pds.4030","volume":"25","author":"Chang","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref31","unstructured":"Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare. Ethical guidelines for epidemiological research. Available from: http:\/\/www.niph.go.jp\/wadai\/ekigakurinri\/guidelines.pdf. Accessed September 25, 2020."},{"key":"ref32","unstructured":"IQVIA. IQVIA report 2018: the impact of biosimilar competition in Europe. Available from: https:\/\/ec.europa.eu\/docsroom\/documents\/31642. Accessed September 25, 2020."},{"key":"ref33","unstructured":"Cabinet Office, Government of Japan. Basic policy on economic and fiscal management and reform 2017. Available from: https:\/\/www5.cao.go.jp\/keizai-shimon\/kaigi\/cabinet\/2017\/2017_basicpolicies_en.pdf. Accessed September 25, 2020."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fphar.2020.00970","volume":"11","author":"Kim","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref35","unstructured":"Japan Interactable Diseases Information Center. Information on medical expenses subsidy system for patients with designated intractable disease. (In Japanese). Available from: https:\/\/www.nanbyou.or.jp\/entry\/5460. Accessed September 25, 2020."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23922\/jarc.2019-003","volume":"4","author":"Okabayashi","year":"2020","journal-title":"J Anus Rectum Colon"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref38","unstructured":"Cabinet Office, Government of Japan. Basic policy on economic and fiscal management and reform 2018. Available from: https:\/\/www5.cao.go.jp\/keizai-shimon\/kaigi\/cabinet\/2018\/2018_basicpolicies_en.pdf. Accessed September 25, 2020."},{"key":"ref39","unstructured":"Cabinet Office, Government of Japan. Basic policy on economic and fiscal management and reform 2019. Available from: https:\/\/www5.cao.go.jp\/keizai-shimon\/kaigi\/cabinet\/2019\/2019_basicpolicies_en.pdf. Accessed September 25, 2020."},{"key":"ref40","unstructured":"Ministry of Health, Labour and Welfare, Japan. National health insurance drug price standard list for injection. (In Japanese). Available from: tp 20201211-01_02.pdf (mhlw.go.jp). Accessed January 21, 2021."},{"key":"ref41","unstructured":"Ministry of Health, Labour and Welfare, Japan. 424th central social insurance medical council document 1\u20131 (54). (In Japanese). Available from: 000522373.pdf (mhlw.go.jp). Accessed January 21, 2021."}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=67085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=67085","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T20:32:29Z","timestamp":1614198749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/changes-in-the-penetration-rate-of-biosimilar-infliximab-within-japan--peer-reviewed-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":41,"URL":"https:\/\/doi.org\/10.2147\/ceor.s293698","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}